Patient-provider Decision Aid for HIV Post-exposure Prophylaxis Following Sexual Assault

Conditions

• Hiv

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• decision aid — BEHAVIORAL
  A digital, interactive patient-provider HIV PEP decision aid. The decision aid will incorporate five sections of content: 1) key clinical factors input by providers; 2) tailored HIV risk sharing information; 3) standardized multimedia educational messaging regarding the effectiveness, risks, and benefits of HIV PEP; 4) direct comparisons of priorities (e.g., physical well-being - "I want to do everything I can to prevent HIV," privacy - "I don't want others to know about the exposure," or cost - "I can't afford the pills'') completed by patients; and 5) tailored feedback regarding patient priorities for use in shared clinical decision making.

Study Details

The goal of this trial is to pilot a digital, interactive patient-provider HIV PEP decision aid. The decision aid will incorporate five sections of content: 1) key clinical factors input by providers; 2) tailored multimedia-based HIV risk sharing information; 3) standardized multimedia educational messaging regarding the effectiveness, risks, and benefits of HIV PEP; 4) direct comparisons of priorities (e.g., physical well-being - "I want to do everything I can to prevent HIV," privacy - "I don't want others to know about the exposure," or cost - "I can't afford the pills'') completed by patients; and 5) tailored feedback regarding patient priorities for use in shared clinical decision making.

Key Dates

Start date

Oct 4, 2024

Status verified

Jul 2025

Primary completion

Jun 30, 2026

Completion

Jun 30, 2026

Study Design

Enrollment

45 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

SUPPORTIVE_CARE

Arms

• Experimental: decision aid
  A digital, interactive patient-provider HIV PEP decision aid. The decision aid will incorporate five sections of content: 1) key clinical factors input by providers; 2) tailored HIV risk sharing information; 3) standardized multimedia educational messaging regarding the effectiveness, risks, and benefits of HIV PEP; 4) direct comparisons of priorities (e.g., physical well-being - "I want to do everything I can to prevent HIV," privacy - "I don't want others to know about the exposure," or cost - "I can't afford the pills'') completed by patients; and 5) tailored feedback regarding patient priorities for use in shared clinical decision making.

Primary Outcome Measure

decisional conflict [ Time Frame: immediately post-intervention ]

Central Contacts

• Melissa Yu
  (916) 360-0149
  [email protected]
• Hannah Aston
  [email protected]

Locations (1)

Find similar trials in Washington D.C., DC

Related Studies

• Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIV
  Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Washington D.C., District of Columbia
• The DC Cohort Longitudinal HIV Status Neutral Study
  Recruiting · George Washington University · Washington D.C., District of Columbia
• Long-term Follow-up of Study Participant Treated With Lentiviral-Based Genetically Modified Autologous Cell Product ,AGT103-T
  Enrolling By Invitation · American Gene Technologies International Inc. · Washington D.C., District of Columbia
• Predictors of Health Service Utilizations Among Key Population in Washington DC
  Recruiting · Us Helping Us, People Into Living, Inc. · Washington D.C., District of Columbia